What's happened
Uganda’s push to expand local pharmaceutical production has shown progress, with procurement from local manufacturers rising to 64% in the 2025/26 year and investments surpassing $500 million. Authorities say policy reforms, expanding product lines and better off-take agreements are needed to sustain growth and shield the sector from global procurement swings.
What's behind the headline?
Analysis
- The data shows a clear shift toward local manufacturing in Uganda, supported by a policy pivot in 2016 and sustained through 2026. This aligns with broader regional efforts to strengthen health security by localizing supply chains.
- The rising share of locally sourced medicines (from ~5% to 64% in 2025/26) signals a successful domestic procurement strategy, but the system risks stagnation if the list of eligible products remains narrow and off-take models tilt toward existing players.
- The most consequential questions center on demand predictability, financing, and the ability of domestic firms to scale across therapeutic areas to meet public and private market needs.
- If demand remains uncertain, private investment could falter, undermining job creation and export potential. A clear, long-term procurement framework will be crucial to sustain growth.
How we got here
Uganda’s government has long promised a domestic pharma industry to reduce reliance on imports. The State House medical team has pressed agencies to expand the list of locally manufactured medicines and ensure fair competition in procurement. Officials cite rising local procurement shares and a ballooning NMS budget as signs of progress, while warning that off-take agreements and product eligibility remain bottlenecks.
Our analysis
- All Africa reports that local procurement rose to 64% in the 2025/26 Financial Year, with NMS budgets expanding from $70 million (2015) to nearly $200 million. Director Ajay Kumar Pal notes product diversification as a key milestone. The Uganda Manufacturers Association notes more than 20 members and 5,000 direct jobs. - The Guardian covers UK debates on domestic military and NHS uniforms, highlighting the broader theme of onshore manufacturing and procurement visibility. - Additional Africa-focused reporting shows Uganda’s ambition to expand capacity with facilities like Quality Chemicals Industries Limited diversifying into hydroxyurea and sickle-cell treatments.
Go deeper
- What concrete steps is Uganda taking to widen the list of locally manufactured medicines beyond 37 products?
- How are off-take agreements being structured to prevent monopolies while spurring new product lines?
- What timelines are policymakers setting for full domestic procurement across all essential medicines?